New Weight Loss Pill Promises Big Slimming Results Without the Needles
A revolutionary new pill from the makers of diabetes drug Mounjaro has smashed expectations in tackling obesity and type 2 diabetes. Orforglipron, a simple once-a-day tablet, helped patients cut nearly 10% of their body weight and drastically lower dangerously high blood sugar levels.
How Orforglipron Works
- Part of the GLP-1 agonist family, like Mounjaro and Wegovy.
- Suppresses appetite and keeps users feeling fuller for longer.
- Unlike injectable rivals, it’s a needle-free pill for easy, convenient use.
- Stable at room temperature and taken anytime, with or without food.
Orforglipron is cheaper and simpler to produce and transport. Drug giant Lilly plans a global release as soon as next year.
Trial Results: Shedding Weight and Controlling Diabetes
More than 1,400 patients across 10 countries took part in a rigorous 72-week trial. They averaged 16 stone (101.4kg) and a BMI of 35.6, with blood sugar levels far above healthy ranges.
- 36mg dose: 9.6% average weight loss and 1.7% drop in HbA1c blood sugar.
- 12mg dose: 7% weight loss and 1.5% HbA1c reduction.
- 6mg dose: 5.1% weight loss and 1.2% HbA1c drop.
- Placebo: Just 2.5% weight loss and 0.5% HbA1c improvement.
Waists shrank by 8.3cm on the highest dose—almost triple the reduction seen with a placebo.
Side effects included mild nausea, vomiting, constipation, or diarrhoea, but were mostly manageable.
Experts Hail Low-Cost Gamechanger for Obesity
“Orforglipron’s safety profile and predicted lower cost will open the door for many more people worldwide needing obesity treatment,” said Dr Deborah Horn, Medical Director at the University of Texas Center for Obesity Medicine. “I hope it will become the ‘metformin’ of obesity—a low-cost, effective, and low-risk option for patients globally.”
While injectable rivals like Mounjaro deliver bigger weight drops of up to 20%, experts say the needle-free pill is “very good news” for those afraid of injections or struggling with needles.
UK Outlook: A Potential NHS Gamechanger
Lilly is expected to apply for NHS approval next year for orforglipron to treat both obesity and diabetes.
With 2.5 million Brits already using weight loss injections and two-thirds of UK adults overweight or obese, the demand is huge. Weight-related health costs hit a staggering £74 billion annually.
This pill could be a major step forward—offering convenience, affordability, and real hope to help Britain fight back against its obesity epidemic.
